美国Moderna新冠疫苗首剂接种后过敏反应包括严重过敏反应的监测分析
截至2021年1月10日,美国接种Moderna新冠疫苗首剂4,041,396剂,VAERS收到1,266例(0.03%)不良事件报告,其中108例疑似严重过敏反应经审查确定10例为严重过敏反应,发生率为每百万剂2.5例。10例中9例有过敏史,5例有严重过敏反应史,症状出现中位时间7.5分钟。
要点
- Moderna新冠疫苗首剂后严重过敏反应发生率为每百万剂2.5例。
- 多数严重过敏反应病例有过敏史或严重过敏反应史。
- 症状出现中位时间7.5分钟,需接种后即时观察。
核心结论
- Moderna新冠疫苗首剂接种后严重过敏反应罕见,但存在,需关注过敏史人群。
研究设计与样本
- 基于VAERS被动监测系统的病例系列分析,截至2021年1月10日美国接种4,041,396剂首剂Moderna新冠疫苗。
主要发现
- VAERS收到1,266例(0.03%)不良事件报告,其中108例疑似严重过敏反应病例经审查确定10例为严重过敏反应。
- 严重过敏反应发生率为每百万剂2.5例,10例中9例有过敏史,5例有严重过敏反应史。
- 症状出现中位时间7.5分钟(范围1-45分钟),8例有随访信息者均康复或出院。
局限性
- 被动监测系统存在报告不足和报告偏倚,部分病例信息不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As of January 20, 2021, a total of 24,135,690 cases of coronavirus disease 2019 (COVID-19) and 400,306 associated deaths had been reported in the United States (https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days). On December 18, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Moderna COVID-19 vaccine administered as 2 doses, 1 month apart to prevent COVID-19. On December 19, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of Moderna COVID-19 vaccine (1). As of January 10, 2021, a reported 4,041,396 first doses of Moderna COVID-19 vaccine had been administered in the United States, and reports of 1,266 (0.03%) adverse events after receipt of Moderna COVID-19 vaccine were submitted to the Vaccine Adverse Event Reporting System (VAERS). Among these, 108 case reports were identified for further review as possible cases of severe allergic reaction, including anaphylaxis. Anaphylaxis is a life-threatening allergic reaction that occurs rarely after vaccination, with onset typically within minutes to hours (2). Among these case reports, 10 cases were determined to be anaphylaxis (a rate of 2.5 anaphylaxis cases per million Moderna COVID-19 vaccine doses administered), including nine in persons with a documented history of allergies or allergic reactions, five of whom had a previous history of anaphylaxis. The median interval from vaccine receipt to symptom onset was 7.5 minutes (range = 1-45 minutes). Among eight persons with follow-up information available, all had recovered or been discharged home. Among the remaining case reports that were determined not to be anaphylaxis, 47 were assessed to be nonanaphylaxis allergic reactions, and 47 were considered nonallergic adverse events. For four case reports, investigators have been unable to obtain sufficient information to assess the likelihood of anaphylaxis. This report summarizes the clinical and epidemiologic characteristics of case reports of allergic reactions, including anaphylaxis and nonanaphylaxis allergic reactions, after receipt of the first dose of Moderna COVID-19 vaccine during December 21, 2020-January 10, 2021, in the United States. CDC has issued updated interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States (3) and interim considerations for preparing for the potential management of anaphylaxis (4).
引用
- Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 33507892. doi:10.15585/mmwr.mm7004e1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。